Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.
Article Details
- CitationCopy to clipboard
Parish D, Scheinfeld N
Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.
Curr Opin Investig Drugs. 2008 Feb;9(2):201-9.
- PubMed ID
- 18246523 [ View in PubMed]
- Abstract
Forest Laboratories (following its acquisition of Cerexa Inc, a spin-out from Peninsula Pharmaceuticals Inc), under license from Takeda, is developing ceftaroline fosamil, an N-phosphono prodrug of ceftaroline, a derivative of a fourth-generation cephalosporin, for the potential treatment of methicillin-resistant Staphylococcus aureus infection. Phase III clinical trials evaluating ceftaroline fosamil for community acquired pneumonia and complicated skin and skin structure infections are underway.
DrugBank Data that Cites this Article
- Drugs